IP Library Granted Patent US 7,153,877
Granted Patent B2
US 7,153,877 · App. 11/009,266 · Granted Dec 26, 2006

Method and composition for preventing or reducing the symptoms of insulin resistance syndrome

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,153,877
App. No.
11/009,266
Granted
Dec 26, 2006
Kind
B2
Abstract

A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.

Claims (10)

1. A composition comprising chromium bound to niacin and three compounds selected from the group consisting of (−) hydroxycitric acid, zinc, trans-resveratrol, gymnernic acid, selenium, an anthocyanidin, allicin, and fenugreek.

2. A composition as defined in claim 1 , wherein the composition further comprises between about 50 and about 1,000 μg chromium bound to niacin.

3. A composition as defined in claim 1 , wherein the composition further comprises between about 250 and about 3,000 mg (−)hydroxycitric acid.

4. A composition as defined in claim 1 , wherein the composition further comprises between about 5 and about 50 mg zinc.

5. A composition as defined in claim 1 , wherein the composition further comprises between about 5 and about 100 mg trans-resveratrol.

6. A composition as defined in claim 1 , wherein the composition further comprises between about 50 and about 200 mg gymnemic acid.

7. A composition as defined in claim 1 , wherein the composition further comprises between about 0.025 and about 0.1 mg selenium.

8. A composition as defined in claim 1 , wherein the composition further comprises between about 5 and about 100 mg of an anthocyanidin.

9. A composition as defined in claim 1 , wherein the composition further comprises between about 2 and about 8 mg allicin.

10. A composition as defined in claim 1 , wherein the composition further comprises between about 100 and about 300 mg of fenugreek.

Assignments (4)
CHANGE OF NAME Recorded Oct 15, 2021
From: INTERHEALTH NUTRACEUTICALS INCORPORATED
To: LONZA CONSUMER HEALTH INC.
Reel/Frame 057828/0594 →
RELEASE OF SECURITY INTEREST Recorded Oct 5, 2016
From: MADISON CAPITAL FUNDING LLC
To: INTERHEALTH NUTRACEUTICALS INCORPORATED
Reel/Frame 040234/0538 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Sep 12, 2016
From: MADISON CAPITAL FUNDING LLC, AS ADMINISTRATIVE AGENT
To: INTERHEALTH NUTRACEUTICALS INCORPORATED
Reel/Frame 040068/0687 →
SECURITY AGREEMENT Recorded Dec 2, 2013
From: INTERHEALTH NUTRACEUTICALS INCORPORATED
To: MADISON CAPITAL FUNDING LLC (AS ADMINISTRATIVE AGENT)
Reel/Frame 031748/0036 →